Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
olanzapine, Quantity: 15 mg
Pharmacor Pty Ltd
Olanzapine
Tablet, film coated
Excipient Ingredients: magnesium stearate; hyprolose; lactose monohydrate; microcrystalline cellulose; hypromellose; crospovidone; titanium dioxide; polysorbate 80; macrogol 400; indigo carmine aluminium lake
Oral
100 Tablets in bottle pack
(S4) Prescription Only Medicine
Olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.,Olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.,Olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.
Visual Identification: Light blue,elliptical, biconvex, film-coated tablets debossed with "O4" on one side and plain on the other side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2012-03-23
Pharmacor Olanzapine (V – 02) 1 AUSTRALIAN PRODUCT INFORMATION – PHARMACOR OLANZAPINE (OLANZAPINE) TABLETS 1 NAME OF THE MEDICINE Olanzapine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The active ingredient in Pharmacor Olanzapine is olanzapine. Excipients with known effect: Contains sugars as lactose monohydrate. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Pharmacor Olanzapine 15 is presented as light blue, elliptical, biconvex, film-coated tablets debossed with “O4” on one side and plain on the other side. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS Pharmacor Olanzapine is indicated for the treatment of schizophrenia and related psychoses. Pharmacor Olanzapine alone or in combination with lithium or valproate is indicated for the short- term treatment of acute manic episodes associated with Bipolar I Disorder. Pharmacor Olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder. 4.2 D OSE AND METHOD OF ADMINISTRATION Olanzapine 2.5 mg, 5 mg, 7.5 mg and 10 mg tablets are unavailable in this brand, however these dosages in tablet form are available in other brands. Schizophrenia and Related Disorders The recommended starting dose for olanzapine is 5-10 mg/day, administered as a single daily dose without regard to meals. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5-20 mg daily. An increase to a dose greater than the routine therapeutic dose of 10 mg/day is recommended only after appropriate clinical reassessment. Acute Mania Associated with Bipolar Disorder The recommended starting dose for olanzapine is 10 or 15 mg administered once a day as monotherapy or 10 mg administered once daily in combination therapy with lithium or valproate. It may be given without regard to meals. Dosage adjustments, if indicated, should generally occur at intervals of not less than 24 hours. When dosage adjustments are necessary, dose Pharmacor Olanzapine (V Read the complete document